Circulating Tumor Cells Market Share, Analysis Report 2024

<h2>Circulating Tumor Cells Market Size, Share, Trends Analysis</h2>
The <strong>circulating tumor cells market</strong> was valued at <strong>USD 14.84 billion</strong> in 2023. It is expected to reach <strong>USD 81.6 billion</strong> by 2033, with a <strong>CAGR of 19.11%</strong> during the forecast period from 2024 to 2033.

<img class="aligncenter wp-image-42953" src="https://marketresearch.biz/wp-content/uploads/2024/01/circulating-tumor-cells-market-by-tech-1.jpg" alt="circulating tumor cells market by tech" width="744" height="454">

The surge in demand for changing lifestyles and the rise in genetic disorders are some of the main key driving factors for the circulating tumor cells market. Circulating tumor cells are an alternative method to study cancer through liquid biopsy. These cells not only disclose the presence of a tumor but also specify that a cancer is developing or spreading. Circulating tumor cells are rare and heterogeneous. This can be also found in the initial stages of cancer.

According to an article published by the American Cancer Society on January 12, 2023, there are more than 1,958,310 new cancer cases and 609,820 cancer deaths reported in the US. Moreover, according to an article published, In India, more than 14,61,427 cancer cases were reported in 2022. Likewise, according to a BMC cancer report in December 2023, circulating tumor cells were reported in 122 out of 125 patients with tumors which has a positive rate of 96.7%.

Circulating tumor cells are seeds for metastases, they preserve tumor heterogeneity and impersonate tumor features that permit them to be used by therapeutic targets and clinical biomarkers for screening the disease, dynamic supervision, and forecasting prognosis. However, circulating tumor cells, which are also known as CTC, are derived 3D organoid models that can be used to screen tests for drug sensitivity and analysis of multiplexed proteomics of circulating tumor cells. Although there are certain restraints, the growth of circulating tumor cells isolation and culture are important for therapy, disease evolution, and actual real-time genomic classification.

Detecting circulating tumor cells is a novel liquid biopsy technology that simplifies accurate diagnosis and treatment of tumors. The circulating tumor cells have several benefits of easy procurement and the potential to offer dynamic monitoring information. Moreover, the usage of live CTCs can get in vitro analysis of tumor morphology and function. The counting of CTCs, molecular typing, and downstream analysis have a wide prospect for applications in tumor efficacy valuation, prognosis assessment, and auxiliary treatment decision-making.

There are several circulating tumor cells identifying methods that have been created which are based on exceptional molecular substances within tumor cells as detection targets to get detection and grouping of tumor cells. Such methodology is highly sensitive and particular and also identifies single tumor cells. Due to some intricacy of tumors, the identifying efficacy of CTCs in varied types of tumors and their practical supervision for the prevalence and development of tumors are issues that require further advancement. The rise of the prevalence of circulating tumor cancer will expand due to its mimic feature with cancer that will help in therapeutic and medical treatment which will also support market expansion in the coming years.

<h2>循环肿瘤细胞市场规模、份额、趋势分析</h2>循环肿瘤细胞市场在2023年估值达到<strong>148.4亿美元</strong>。预计到2033年将达到<strong>816亿美元</strong>，在2024年至2033年预测期间，其年复合增长率(CAGR)将达到19.11%。<br><img class="aligncenter wp-image-42953" src="https://marketresearch.biz/wp-content/uploads/2024/01/circulating-tumor-cells-market-by-tech-1.jpg" alt="循环肿瘤细胞市场按技术分类" width="744" height="454"><br>生活方式的改变和遗传疾病增加的势头是推动循环肿瘤细胞市场增长的主要关键因素。循环肿瘤细胞是研究癌症的液体活检的替代方法。这些细胞不仅揭示了肿瘤的存在，还表明癌症正在发展或扩散。循环肿瘤细胞稀少且异质，这也可能出现在癌症的早期阶段。<br>根据美国癌症协会于2023年1月12日发表的文章，美国报告了超过1,958,310例新发癌症病例和609,820例癌症死亡。此外，根据发表的文章，2022年印度报告了超过14,61,427例癌症病例。同样，根据2023年12月发布的BMC癌症报告，在125名肿瘤患者中，有122名患者检测到循环肿瘤细胞，阳性率为96.7%。<br>循环肿瘤细胞是转移的种子，它们保留了肿瘤的异质性，并模拟肿瘤特征，使其能够被用作治疗靶点和临床生物标志物，用于疾病的筛查、动态监督和预后预测。然而，循环肿瘤细胞（也称为CTC）是源自3D器官样模型的细胞，可用于筛选药物敏感性测试和分析循环肿瘤细胞的蛋白质组学。尽管存在某些限制，但循环肿瘤细胞的分离和培养对于治疗、疾病演变和实时基因组分类至关重要。<br>检测循环肿瘤细胞是一种新颖的液体活检技术，它简化了肿瘤的准确诊断和治疗。循环肿瘤细胞具有易于获取和提供动态监测信息的优势。此外，使用活循环肿瘤细胞可以进行体外肿瘤形态和功能的分析。CTC计数、分子分型和下游分析在肿瘤疗效评估、预后评估和辅助治疗决策中的应用前景广阔。<br>已经开发出多种循环肿瘤细胞鉴定方法，这些方法基于肿瘤细胞内独特的分子物质作为检测靶标，以实现肿瘤细胞的检测和分类。此类方法具有高度灵敏性和特异性，并能识别单个肿瘤细胞。由于肿瘤的某些复杂性，CTC在肿瘤不同类型中的识别效率以及它们在肿瘤流行和进展中的实际监督是需要进一步发展的课题。循环肿瘤癌症的流行率上升，由于其与癌症的相似特征，将有助于治疗和医疗治疗，也将支持未来几年的市场扩张。